What is OnKure Therapeutics, Inc.?
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 108.33M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 2387 shares $2k | 0 |
| 9-12months | 2389 shares $1k | 0 |